表紙
市場調査レポート

ハンチントン病:パイプライン製品の分析

Huntington Disease - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 362369
出版日 ページ情報 英文 303 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
ハンチントン病:パイプライン製品の分析 Huntington Disease - Pipeline Review, H1 2016
出版日: 2016年05月31日 ページ情報: 英文 303 Pages
概要

当レポートでは、ハンチントン病治療薬の開発状況について調査しており、パイプライン製品の概要、治験段階別の製品概要、主要企業および薬剤のプロファイル、パイプライン製品の最新動向、および最新ニュース/プレスリリースなどを提供しています。

イントロダクション

ハンチントン病の概要

治療薬の開発

ハンチントン病:企業で開発中の治療薬

ハンチントン病:大学/機関で研究中の治療薬

ハンチントン病:パイプライン製品の概況

ハンチントン病:企業で開発中の製品

ハンチントン病:大学/機関で研究中の製品

ハンチントン病の治療薬開発に従事している企業

ハンチントン病:治療薬の評価

薬剤プロファイル

ハンチントン病:最近のパイプライン動向

ハンチントン病:休止中のプロジェクト

ハンチントン病:開発が中止された製品

ハンチントン病:製品開発のマイルストーン

付録

目次
Product Code: GMDHC8162IDB

Summary

Global Markets Direct's, 'Huntington Disease - Pipeline Review, H1 2016', provides an overview of the Huntington Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Huntington Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Huntington Disease and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Huntington Disease
  • The report reviews pipeline therapeutics for Huntington Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Huntington Disease therapeutics and enlists all their major and minor projects
  • The report assesses Huntington Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Huntington Disease

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Huntington Disease
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Huntington Disease pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Huntington Disease Overview
  • Therapeutics Development
  • Huntington Disease - Therapeutics under Development by Companies
  • Huntington Disease - Therapeutics under Investigation by Universities/Institutes
  • Huntington Disease - Pipeline Products Glance
  • Huntington Disease - Products under Development by Companies
  • Huntington Disease - Products under Investigation by Universities/Institutes
  • Huntington Disease - Companies Involved in Therapeutics Development
  • Huntington Disease - Therapeutics Assessment
  • Drug Profiles
  • Huntington Disease - Recent Pipeline Updates
  • Huntington Disease - Dormant Projects
  • Huntington Disease - Discontinued Products
  • Huntington Disease - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Huntington Disease, H1 2016
  • Number of Products under Development for Huntington Disease - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Huntington Disease - Pipeline by Addex Therapeutics Ltd, H1 2016
  • Huntington Disease - Pipeline by AFFiRiS AG, H1 2016
  • Huntington Disease - Pipeline by Angita B.V., H1 2016
  • Huntington Disease - Pipeline by Astellas Pharma Inc., H1 2016
  • Huntington Disease - Pipeline by Azevan Pharmaceuticals, Inc., H1 2016
  • Huntington Disease - Pipeline by BioCrea GmbH, H1 2016
  • Huntington Disease - Pipeline by BioMarin Pharmaceutical Inc., H1 2016
  • Huntington Disease - Pipeline by BrainStorm Cell Therapeutics Inc., H1 2016
  • Huntington Disease - Pipeline by Diffusion Pharmaceuticals Inc., H1 2016
  • Huntington Disease - Pipeline by EncephRx, Inc., H1 2016
  • Huntington Disease - Pipeline by Evotec AG, H1 2016
  • Huntington Disease - Pipeline by Galenea Corp., H1 2016
  • Huntington Disease - Pipeline by Genervon Biopharmaceuticals, LLC, H1 2016
  • Huntington Disease - Pipeline by Immungenetics AG, H1 2016
  • Huntington Disease - Pipeline by Ionis Pharmaceuticals, Inc., H1 2016
  • Huntington Disease - Pipeline by Ipsen S.A., H1 2016
  • Huntington Disease - Pipeline by Kadmon Corporation, LLC, H1 2016
  • Huntington Disease - Pipeline by KineMed, Inc., H1 2016
  • Huntington Disease - Pipeline by Living Cell Technologies Limited, H1 2016
  • Huntington Disease - Pipeline by Medesis Pharma S.A., H1 2016
  • Huntington Disease - Pipeline by Mitochon Pharmaceuticals, Inc., H1 2016
  • Huntington Disease - Pipeline by Neuralstem, Inc., H1 2016
  • Huntington Disease - Pipeline by Neurimmune Holding AG, H1 2016
  • Huntington Disease - Pipeline by NeuroNascent, Inc., H1 2016
  • Huntington Disease - Pipeline by New World Laboratories, Inc., H1 2016
  • Huntington Disease - Pipeline by nLife Therapeutics, S.L., H1 2016
  • Huntington Disease - Pipeline by NsGene A/S, H1 2016
  • Huntington Disease - Pipeline by Omeros Corporation, H1 2016
  • Huntington Disease - Pipeline by Oryzon Genomics S.A., H1 2016
  • Huntington Disease - Pipeline by Otsuka Holdings Co., Ltd., H1 2016
  • Huntington Disease - Pipeline by Pfizer Inc., H1 2016
  • Huntington Disease - Pipeline by PharmatrophiX, Inc., H1 2016
  • Huntington Disease - Pipeline by ProQR Therapeutics N.V., H1 2016
  • Huntington Disease - Pipeline by QR Pharma, Inc., H1 2016
  • Huntington Disease - Pipeline by Raptor Pharmaceutical Corp., H1 2016
  • Huntington Disease - Pipeline by reMYND NV, H1 2016
  • Huntington Disease - Pipeline by Rhenovia Pharma Limited, H1 2016
  • Huntington Disease - Pipeline by Sangamo BioSciences, Inc., H1 2016
  • Huntington Disease - Pipeline by SOM Innovation Biotech SL, H1 2016
  • Huntington Disease - Pipeline by Spark Therapeutics, Inc., H1 2016
  • Huntington Disease - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016
  • Huntington Disease - Pipeline by TyrNovo Ltd., H1 2016
  • Huntington Disease - Pipeline by Ultragenyx Pharmaceutical Inc., H1 2016
  • Huntington Disease - Pipeline by UniQure N.V., H1 2016
  • Huntington Disease - Pipeline by Vaccinex, Inc., H1 2016
  • Huntington Disease - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016
  • Huntington Disease - Pipeline by VistaGen Therapeutics , Inc., H1 2016
  • Huntington Disease - Pipeline by VivaCell Biotechnology Espana S.L., H1 2016
  • Huntington Disease - Pipeline by Voyager Therapeutics, Inc., H1 2016
  • Huntington Disease - Pipeline by Vybion, Inc., H1 2016
  • Huntington Disease - Pipeline by WAVE Life Sciences Ltd., H1 2016
  • Huntington Disease - Pipeline by Wellstat Therapeutics Corporation, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Huntington Disease Therapeutics - Recent Pipeline Updates, H1 2016
  • Huntington Disease - Dormant Projects, H1 2016
  • Huntington Disease - Dormant Projects (Contd..1), H1 2016
  • Huntington Disease - Dormant Projects (Contd..2), H1 2016
  • Huntington Disease - Dormant Projects (Contd..3), H1 2016
  • Huntington Disease - Dormant Projects (Contd..4), H1 2016
  • Huntington Disease - Dormant Projects (Contd..5), H1 2016
  • Huntington Disease - Dormant Projects (Contd..6), H1 2016
  • Huntington Disease - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Huntington Disease, H1 2016
  • Number of Products under Development for Huntington Disease - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top